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The primary activation pathway of T cells is via the T-cell 
receptor (TCR)/CD3 complex, which is functionally interre- 
lated with various accessory molecules. We examined the 
contribution of the lymphocyte-function-associated antigen- 
IIintercellular adhesion molecule I (LFA- IIICAM- I) interac- 
tion to CD3mCR-mediated lysis by cytotoxic T lymphocytes 
(CTL). We used ICAM-IPor+ tumor cell lines as target cells 
and anti-CD3- or anti-LFA-I containing hetero-cross-linked 
monoclonal antibody (MAb) to bridge CTL and target cells 
and simultaneously to activate CTL. The ICAM-I- mela- 
noma-derived cell line lgR39 was relatively resistant to CD3- 
mediated lysis by both TCRaP+ and TCRyG+ CTL, when 
compared with ICAM-I+ cell lines. Induction of ICAM-I on 
the membrane of lgR39 cells by tumor necrosis factor (TNF) 
rendered these cells more susceptible to CD3-mediated lysis. 
Anti-ICAM-I MAb inhibited this TNF-enhanced susceptibility 
to lysis, directly demonstrating that the induction of ICAM-I 
was critical in the TNF-induced increase in susceptibility to 
lysis of IgR39 cells. CTL formed less efficient conjugates with 
the ICAM- I - cells as compared to ICAM- I + cells. Both spon- 
taneous and CD3-induced conjugate formation as well as 
CD3-mediated lysis of ICAM-I- tumor cells by CTL were en- 
hanced by the addition of anti-LFA-I containing hetero- 
cross-linked MAb, thereby mimicking the LFA- IIICAM- I in- 
teraction between CTL and target cells. Soluble anti-CD I8 
MAb inhibited CD3-mediated lysis of ICAM- I- target cells by 
CTL without affecting their conjugate formation. Anti-LFA- I 
MAb added after conjugate formation st i l l  inhibited lysis of 
both ICAM- I +Or- tumor cells. Taken together, these findings 
suggest that the LFA- IIICAM- I interaction co-activates CD3I 
TCR-mediated lysis by CTL through both an enhanced CTL- 
target cell binding and the delivery of post-conjugate co- 
stimulatory signals. 
T cells can be activated by the antigen-specific T-cell recep- 
tor (TCR) interacting with non-self major histocompatibility 
complex (MHC) proteins or foreign antigen associated with 
self MHC proteins (Ashwell and Schwartz, 1986; Martz, 
1977). Lymphocytes may also be activated via non-polymor- 
phic cell-surface receptors such as CD2, CD3 or CD16 inter- 
acting with their ligands or monoclonal antibody (MAb) 
(Meuer et al., 1984; Bolhuis et al., 1986; Van de Griend et al., 
1987). Recent evidence suggests that these activation sites are 
functionally interrelated, for instance, activation via CD2 can 
be regulated via CD3 and vice versa (Van de Griend et al., 
1987; Goedegebuure et a l . ,  1989). 
The interaction between cytotoxic T lymphocytes (CTL) and 
the relevant target cells results in target-cell lysis by a multi- 
step process (Martz, 1977; Mentzer et al., 1987). The initial 
adhesion step is the rapid formation of an intercellular bond 
(conjugate formation) which is antigen-independent. Two ma- 
jor pathways of adhesion have been identified. First, lympho- 
cyte-function-associated antigen- 1 (LFA- 1) on CTL interacts 
with intercellular adhesion molecule-1 (ICAM-1) on the target 
cell (Shaw et al., 1986; Makgoba et al.,  1988~).  Second, the 
effector cell CD2 interacts with LFA-3 on the target cell (Sel- 
varaj et al., 1987; Dustin et al . ,  1987; Takai et al., 1987; 
Hunig et al., 1987). Subsequently, antigen recognition via the 
TCR results in triggering of the CTL lytic machinery and tar- 
get-cell lysis (Martz, 1977). 
LFA- 1 is a trans-membrane heterodimer composed of a 180- 
kDa cx chain (CDlla) and a 95-kDa P chain (CD18) which is 
expressed by most leukocytes (Springer et al., 1987; Martz, 
1987; Krensky et al., 1983). In addition to its adhesion func- 
tion, LFA-1 is also thought to be involved in T-cell activation, 
possibly as a signal transduction molecule, as reported for CD2 
(Hunig et al., 1987). Binding of anti-LFA-la or anti-LFA-1P 
MAbs to T cells has been shown to up- or down-regulate, 
respectively, anti-CD3 MAb-triggered T-cell proliferation in 
the absence of intercellular adhesion (Van Noesel et al., 1988). 
In mice, anti-LFA- la MAb enhances proliferative responses of 
pre-activated T and B lymphocytes (Pircher et al., 1986; 
Mishra et al., 1986). Finally, a unique anti-LFA-la MAb 
induces homotypic cell-cell interactions (Keizer et al., 1988). 
ICAM-1 is a monomeric 90-114-kDa glycoprotein which 
can be expressed on cells of many lineages, especially at spe- 
cific differentiation stages or after exposure of cells to certain 
inflammatory mediators in vitro or in vivo (Dustin et al., 
1986). Biochemical and functional studies have conclusively 
demonstrated that ICAM-1 is one of the ligands for LFA-I 
(Makgoba et al., 1988a,b; Marlin and Springer, 1987; Sim- 
mons et al., 1988; Rothlein et al., 1986). Target-cell ICAM-1 
is involved in adhesion to and lysis of target cells; however, 
demonstration of this role is restricted to target cells which 
express ICAM-1 as the major LFA-1 ligand (Makgoba et al., 
1988b). Furthermore, ICAM-1 is a major contributor to a va- 
riety of other T-cell responses dependent on cell-cell interac- 
tion (Boyd et al., 1988; Dougherty et al., 1988; Altmann et 
al . ,  1989; Schulz el al . ,  1988). A previously suggested second 
ligand for LFA-1, i .e . ,  ICAM-2, has been identified (Staunton 
et al., 1989). However, at this point it is unclear whether 
binding of the LFA-1 to the ICAM-1 ligand molecule not only 
facilitates the adhesion of the effector cell to the target cell, but 
also mediates signals that regulate CTL activation. 
Lysis-resistant Burkitt's lymphoma cells express low levels 
of LFA-1, LFA-3 and ICAM-1 (Gregory et al., 1988a; Billaud 
et al., 1987). Epstein-Barr virus (EBV)-positive biopsy cells 
with a low expression of these molecules are relatively resistant 
to lysis by specific CTL. Prolonged in vitro culture of these 
cells induces an increased expression of the molecules which is 
associated with a more efficient interaction with specific CTL. 
These findings prompted speculation that the lack of expres- 
sion of ICAM-1 and other adhesion molecules on tumor cells 
contributes to their escape from immunosurveillance (Gregory 
et al., 1988a,b; Clayberger et al., 1987). 
The importance of the LFA-l/ICAM-1 interaction led us to 
further study its involvement in CTL/target-cell conjugate for- 
mation and triggering of lysis. To this end, we used ICAM- 
1-positive or -negative tumor-cell lines as target cells and bi- 
specific Ab-heteroconjugates, containing an anti-CD3 MAb 
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which is covalently coupled to an anti-DNP antibody. Such 
bispecific reagents efficiently bridge effector cells and trini- 
trobenzene sulfonate (TNP)-modified target cells and simul- 
taneously trigger the lytic machinery of the effector cell 
(Goedegebuure et al . ,  1989; Karpovsky et al.,  1984). Our data 
demonstrate that induction of ICAM-1 expression on target 
cells enhances their susceptibility to CD3-triggered lysis. As- 
sociated findings suggest that this co-stimulatory effect results 
from enhanced conjugate formation as well as enhanced signal 
transduction by LFA- MCAM- 1 interactions. 
MATERIAL AND METHODS 
Cytoto.ric clones 
CTL clones were obtained by limiting dilution cloning under 
polyclonal activation conditions as we described earlier (Van 
de Griend et al.,  1987). In short, CTL clones were expanded 
in 96-well round-bottomed microtiter plates (Greiner Labor 
Technik, Phidelsheim, FRG). One to 3 X lo3 cloned CTL per 
well were stimulated with a mixture of irradiated (25 Gy) al- 
logeneic PBL (2 X lo4) and l X lo4 Epstein-Barr virus 
(EBV)-transformed lymphoblastoid B-cell lines (BSM and 
APD) in a final volume of 200 p.1. The culture medium was 
RPMI 1640 (Flow Laboratories, Rockville, MD) buffered with 
bicarbonate (2 g/l) and HEPES (4.8 g/l) and supplemented with 
10% non-heat-inactivated (pooled) human serum, 25 U/ml re- 
combinant IL-2 (EuroCetus, Amsterdam, The Netherlands), 4 
m~ glutamine, 100 IU/ml penicillin and streptomycin, 1 p.g/ml 
indomethacin and 1 pg/ml leukoagglutinin (HA15, Phannacia, 
Uppsala, Sweden). Clones were harvested and replated with 
new feeder cells and fresh medium at weekly intervals. 
Antibodies 
Bispecific hetero-cross-linked antibodies (Abs) were pre- 
pared with the use of the cross-linking reagent N-succini- 
midyl-3-(2-pyridyldithiol propionate) (SPDP) as described in 
detail elsewhere (Karpovsky et al . ,  1984). Hetero-cross-linked 
Abs used in this study were: anti-CD3 (OKT3) x anti-DNP; 
anti-CD18 (MHM23) x anti-DNP and anti-HLA Class I 
(W6/32) X anti-DNP MAb. Anti-DNP Abs were purified 
polyclonal rabbit Abs. MAbs used for the inhibition of lym- 
phocyte functions and for immunofluorescence staining were: 
CLB54 (anti-CD18) (Miedema et al.,  1984), specific for the 
LFA-1P chain, a generous gift from Dr. R.A.W. van Lier 
(CLB, Amsterdam, The Netherlands); MAb 84H10 (anti- 
ICAM-1) (Makgoba et al . ,  1988a) and W6/32 (anti-HLA 
Class-I common epitope) (Barnstable et al . ,  1978). 
Cytotoxicity assay 
Cytotoxic activity was measured in a standard 3-hr 5'Cr 
release assay (Van de Griend et al.,  1987; Goedegebuure et 
al.,  1989). Briefly, varying numbers of effector cells were 
added in triplicate in 75 pl/well in 96-well round-bottomed 
microtiter plates. The hetero-cross-linked Ab (75 p.1) was 
added to the microtiter well at the indicated concentrations 30 
min before addition of SICr-labelled target cells (100 pl). Tar- 
get cells were incubated with 0.3 m~ trinitrobenzene sulfonate 
(TNP) for 15 min at 37°C and then washed. ICAM-1 expres- 
sion on IgR39 tumor cells was enhanced by incubation with 
1000 U/ml recombinant human tumor necrosis factor (recTNF) 
(Cetus Corp., Emeryville, CA) for 24 h. Tumor cell lines used 
as target cells in this study include IgR39 and IgR37, mela- 
noma-derived cell lines: Licr-Lon, a leukemic plasma cell line: 
Molt-4, a T-cell line, APD, an EBV-transformed B-cell line: 
K562, an erythromyeloid cell line and U937, a monocytic cell 
line (Van de Griend et al.,  1987). 
Hetero-cross-linked Ab-induced cytotoxicity was blocked 
with MAb by the simultaneous addition of 50 p.1 blocking MAb 
and 50 p1 heteroconjugated Ab to 50 p1 effector cells 30 min 
prior to the addition of 100 p.1 target cells, unless indicated 
otherwise. The standard error of the mean percentage lysis 
never exceeded 5% and was omitted for clarity of presentation. 
Conjugate formation assay 
Antigen-independent and hetero-cross-linked Ab-induced 
conjugate formation of CTL and target cells was assessed by 
FACS analysis (Becton Dickinson, Mountain View, CA) 
(Makgoba et al.,  1988a; Perez et al . ,  1985; Leo et al.,  1987). 
CTL (5 x lo6) were labelled with LOO p.g/ml hydroethidine in 
a volume of 2 ml at 37°C for 25 min. Target cells (5 X lo6) 
were first modified with TNP (see above) and then labelled 
with 0.05 p g / d  carboxy fluorescein diacetate (CFDA) in a 
volume of 2 ml at 37°C for 25 min. CTL and target cells were 
washed before use. Twenty microliters of labelled effector 
cells (107/ml) were mixed with an equal amount of labelled 
target cells ( 107/ml) with and without Ab-heteroconjugates 
and/or blocking MAb. Ab-heteroconjugates and MAb were 
preincubated with the CTL for 15 min at 37°C before the 
addition of tumor target cells. The final volume was adjusted to 
100 ~ 1 .  Conjugate assay medium was RPMI 1640 supple- 
mented with 10% FCS. CTL and target-cell mixtures were 
centrifuged for 5 sec in a serofuge and conjugates were allowed 
to form at 21°C for 10 min. Conjugate formation was stopped 
by the addition of 1 ml ice-cold PBS + 1% BSA. Cells were 
immediately resuspended and analyzed on a FACScan. Ten 
thousand total fluorescent events were collected and the num- 
ber of events simultaneously emitting red and green fluores- 
cence (conjugates) was divided by the total number of events 
emitting red fluorescence (total effector cells) yielding the per- 
centage of CTL that had formed conjugates. No conjugates 
were observed when CTL and target cells were mixed and 
analyzed immediately. 
Immunojluorescence assay 
Five hundred thousand cells were pelleted and incubated 
with 10-20 p1 MAb at 4°C for 30 min. After washing, the cells 
were incubated with 10 p1 1:40 diluted goat anti-mouse, con- 
jugated with FITC (Nordic, Tilburg, The Netherlands). The 
cells were washed twice with PBS + 1% BSA + 0.01% so- 
dium azide and analyzed on the FACScan. 
RESULTS 
Melanoma IgR39 is relatively resistant to CD3-mediated lysis 
A panel of histologically distinct tumor cell lines were com- 
pared in their susceptibility to lysis by TCRaP+/CD3+ and 
TCRy8 + /CD3 + CTL clones triggered via CD3, using hetero- 
cross-linked anti-CD3 X anti-DNP. Most tumor cell lines 
were susceptible to CD3-mediated lysis (Fig. 1). The mela- 
noma-derived cell line IgR39, however, showed a relative re- 
sistance to CD3-mediated lysis. This was found for both 
TCRaP + and TCRy8 + CTL and hence is independent of the 
sublineage of the CTL. 
The level of CD3-mediated lysis depended on the amount of 
anti-CD3 added. At higher anti-CD3 concentrations (15 ng/ml 
or more) the tumor-cell line IgR39 was effectively lysed (Fig. 
1). Thus, the relative resistance to CD3-mediated lysis of 
IgR39 melanoma cells by cloned TCRaP + and TCRy8 + CTL 
can be overcome at higher effective densities of anti-CD3 MAb 
on the target cells. 
Expression of cellular adhesion molecules on tumor cells 
Because the relative resistance of IgR39 melanoma cells to 
CD3-mediated lysis was independent of the type of CTL clone 
used, we hypothesized that the composition of surface mole- 
cules on the target cells, particularly the known ligands for 
CTL/target-cell interaction ICAM- 1 and LFA-3, determined its 
relative resistance to CD3-mediated lysis by CTL. The TNP 
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modification of the IgR39 cells was not the cause of the relative 
resistance because IgR39 target cells reportedly showed levels 
of sensitivity to CD2-mediated lysis comparable to those of 
other tumor cell lines (Goedegebuure et al . ,  1989). The ex- 
pression of LFA-3 and ICAM-1 on the tumor cell lines was 
then determined. Contrary to the panel of other cultured tumor 
cells tested in Figure 1, the IgR39 cells lacked surface expres- 
sion of ICAM-1 (Fig. 2). All human tumor cell lines tested 
here expressed LFA-3. TNP modification of the tumor cell 
lines did not affect expression of ICAM-1 and LFA-3 (data not 
shown). 
The ‘ ‘resistance” of IgR39 target cells to CD3-mediated lysis is 
due to lack of ICAM-1 expression 
To assess the functional correlation between lack of ICAM-1 
expression and “resistance” to CD3-mediated lysis, we used 
Log fluoreacance intenaity 
*lo00 Ulml rTNF for 24 hra 
FIGURE 2 - TNF induces ICAM-1 expression on the ICAM-1- 
melanoma cell line IgR39. IgR39 was cultured in the presence of 1000 
U/ml recTNF for 24 hr. 
TNF which is known to induce ICAM-1 expression on many 
cell types (Dustin et al.,  1986). Incubation of IgR39 cells with 
1000 U/ml recTNF for 24 hr induced ICAM-1 expression as 
determined by FACS-analysis (Fig. 2). This expression of 
ICAM-1 was accompanied by a simultaneous increase in sus- 
ceptibility to CD3-mediated lysis (Fig. 3). Further evidence 
that ICAM-1 is the critical factor determining the susceptibility 
to CD3-mediated lysis of IgR39 target cells comes from anti- 
ICAM-1 MAb inhibition studies. ICAM-1 specific MAb again 
abolished the increased levels of CD3-mediated lysis of IgR39 
target cells obtained by TNF treatment (Fig. 3). Indeed, the 
level of lysis of TNF-untreated ICAM-1- IgR39 cells was, as 
expected, not affected by anti-ICAM-1 MAb. Thus, TNP- 
induced expression of ICAM-1 can account for the TNF- 
induced increase in susceptibility of IgR39 target cells to CD3- 
mediated CTL lysis. 
Signalling properties of LFA-I in CTL activation 
To examine the signalling abilities of LFA-1 in the actha- 
tion of the lytic machinery of CTL, we tested the effect of 
anti-CD18 (LFA-I p) MAb on spontaneous and anti-CD3 MAb 
induced conjugate formation and cytolysis. As shown in Table 
I, anti-CD18 MAb, as expected, inhibited spontaneous conju- 
gate formation of CTL with ICAM-1 + Licr-Lon cells but min- 
imally with ICAM-1- IgR39 cells. The latter also suggests 
that ICAM-1- IgR39 cells lack sufficient expression of alterna- 
tive ligands for LFA-1 (e.g.  ICAM-2) (Staunton et d.,  1980). 
Anti-CD3 MAb containing heteroconjugated Ab enhanced the 
percentage conjugates formed between CTL and tumor cel Is. 
CD 18-specific MAb had virtually no inhibitory effect on CD3- 
mediated conjugate formation of CTL to ICAM-1 + O r -  tumor 
cells (Table I), but did inhibit CD3-mediated lysis of either 
ICAM-1 +Or-  target cells (Fig. 4). Interestingly, this signifi- 
cant inhibitory effect of CD18-specific MAb on lysis contrasts 
with the marginal inhibitory effects on conjugate formation. 
These findings point to a regulatory role for LFA-1 in CD3- 
mediated CTL activation post CTL/target-cell conjugate for- 
mation. 
Anti-CDl8 X anti-DNP hetero-cross-linked Ab coactivates 
CD3-mediated lysis of ICAM-I - target cells 
Experiments were designed to mimic LFA- l/ICAM- 1 inter- 
% l y s i s  at E/T 10 
0 1 4 15 0 1 4 15 
CD3/DNP (ng/rnl) 
FIGURE 3 - Anti-ICAM-1 MAb abolishes the increased susceptibil- 
ity of TNF-treated IgR39 cells to CD3-mediated lysis by 
TCRyS+/CD3+ clone WiK (panel a) and TCRaP+/CD3+ clone ID1 1 
(panel b). IgR39 cells were cultured with or without 1,OOO 1J/ml 
recTNF for 24 hr and TNP-modified before use as target cells. Hetero- 
cross-linked anti-CD3 MAb and anti-ICAM-1 MAb (84 H10, dilution 
1/1,000 of ascites) were added simultaneously to the CTL eFfec- 
tors prior to the addition of target cells 0, IgR39, m, IgR39 + anti-ICAM-1 MAb; 0, TNF-treated IgR39 and 0, TNF-treated 
IgR39 + anti-ICAM-1 MAb. 
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TABLE I - INHIBITION OF CONJUGATE FORMATION BY ANTI-CDIS 
(LFA-1P) MAb 
Percentage conjugates4 
between TCRy8+ CTL’ and 
ICAM-I + ICAM-I 
Anti-CD1S TNP-target cells Addition of 
heternonjugate’ MAb’ 
(Licr-Lon) (IgRW 
34 23 + 17 19 
52 35 Anti-CD3 - 
Anti-CD3 + 48 31 
‘TCR$+ effector cell: WiK.-’Heteroconjugate concentration 1 Fg/ml. 
-3Anti-CD1B (CLB54 ascites, l/10DO).-4For calculation of percentage conjugates see 
“Material and Methods”. 
- - 
- 
X anti-DNP 
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Percentage lysis at EIT 10 “1 A 
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FIGURE 4 - Anti-CD18 MAb inhibits CD3-mediated lysis of 
ICAM-1- IgR39 cells (panel a) or ICAM-1 + Licr-Lon cells (panel b) 
by TCRys+/CD3+ clone WiK. Target-cell lysis is induced by the 
indicated concentration of anti-CD3 MAb in the absence (solid bars) 
or presence (hatched hars) of anti-CD18 MAb (CLB54, 1/1000 of 
ascites). 
actions, using anti-CD18 X anti-DNP hetero-cross-linked Ab. 
Addition of anti-CD18 X anti-DNP Ab-heteroconjugate in- 
creased the susceptibility of ICAM-1- IgR39 target cells to 
CD3-mediated lysis by TCRc$+ CTL (Table II). Similar re- 
sults were obtained using TCRyS+ CTL (Table 111). The sus- 
ceptibility to lysis of ICAM-I+ target cells was much less 
affected (Table HI). Remarkably, antLCD18 X anti-DNP Ab 
alone also considerably enhanced the MHC-unrestricted lysis 
of ICAM-1- but not ICAM-1 + target cells by TCRy8’ CTL. 
Control, anti-HLA Class I X anti-DNP Ab had no effect on 
MHC-unrestricted or CD3-mediated lysis. 
A N  ET AL. 
TABLE I1 - ANTI-CDIS X ANTI-DNP Ab CO-ACTIVATES LYSIS OF ICAM-I- 
TARGET CELL BY TCRaP CTL 
Addition of 
Ab heteroconjugates 
Percentage lysis of ICAM-I 
IgR39 by TCRUP’ clones 
Clone D1 I Clone 75 
1 0 
aCD18 X aDNP 0 0 
aCD3 X aDNP 37 37 
aCD3 X aDNP 
- 
+ 70 68 
aCD18 X aDNP 
~~ 
Effector to target cell ratio of 7 (clone Dl I j .  14 (clone 75). Heteroconjugate 
concentration aCD3 X aDNP 25 Fg/ml; aCD18 X aDNP 25 pg/ml. 
DISCUSSION 
Initiation of CD3/TCR complex-mediated T-cell functions is 
believed to be interrelated with various accessory molecules. 
The transmembrane molecule LFA-1 is one of the most im- 
portant accessory molecules. Here, we have studied the con- 
tribution of the LFA- UICAM- 1 interaction to CDUTCR com- 
plex-mediated lysis by TCRolP + and TCRyS + CTL at differ- 
ent stages of the lytic cycle. The use of hetero-cross-linked 
anti-CD3 x anti-DNP Ab makes it possible to compare the 
susceptibilities to lysis of different tumor cell lines by an in- 
dividual CTL clone. An ICAM-1- melanoma tumor cell line 
IgR39 shows a relative resistance to CD3/TCR-mediated cy- 
tolysis by TCRaP+ as well as by TCRyS+ cloned lympho- 
cytes. The low susceptibility of IgR39 tumor cells to CD3/ 
TCR-mediated cytolysis was directly related to the lack of 
ICAM- 1 expression because TNF treatment of ICAM-1- 
IgR39 cells induced ICAM- 1 expression and indeed simulta- 
neously increased susceptibility to CD3/TCR-mediated cytol- 
ysis. The IgR39 cell line is not sensitive to TNF lysis (data not 
shown). Moreover, anti-ICAM-1 MAb down-regulated this 
TNF-induced, increased susceptibility to lysis, demonstrating 
that it was functionally due to up-regulation of ICAM- 1 and not 
other unknown ligands. 
The relative resistance of IgR39 cells to CD3-mediated cy- 
tolysis can be overcome by higher concentrations of anti-CD3 
MAb. Thus, an efficient LFA-UICAM-1 interaction may 
lower the requirement for either high antigen density on target 
cells or, alternatively, may compensate for a low-affinity TCR 
on CTL by establishing a more effective CTL-target-cell inter- 
action. 
The interaction between CTL and target cells, resulting in 
target cell lysis, is a multi-step process (Martz, 1977; Mentzer 
et al., 1987). Thus the relative resistance of the ICAM-1- 
IgR39 target cells to CDYTCR-mediated lysis may reflect ei- 
ther a less efficient conjugate formation, or a decreased level of 
activation of the lytic machinery. This study shows that CTL 
formed conjugates less efficiently with ICAM-1- than with 
ICAM-1 + tumor cells. Hetero-cross-linked anti-CD3 MAb en- 
hanced conjugate formation with both the ICAM-1-negative 
and -positive target cells. Addition of anti-CD18 X anti-DNP 
Ab increased spontaneous and CD3-mediated conjugate for- 
mation with the ICAM- 1 - cell line and consequently enhanced 
CD3/TCR-mediated lysis of this target cell. Hetero-cross- 
linked antLCD1 8 MAb failed to enhance CD3/TCR-mediated 
lysis of ICAM-l+ tumor cells, because it could not further 
enhance the relatively efficient conjugate formation with this 
target. It was remarkable that hetero-cross-linked anti-HLA 
Class I did not enhance CD3-mediated conjugate formation 
with the ICAM-1- target cells (data not shown) and therefore 
did not affect CD3-mediated lysis. 
Our data suggest that the relative resistance to CD3- 
mediated lysis of the ICAM-1 - tumor cells is not exclusively 
associated with decreased conjugate formation. The LFA- 
l/ICAM-l interaction also appears to synergize with CD3/ 
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TABLE III - ANTI-CD18 X ANTI-DNP Ab CO-ACTIVATES LYSIS OF THE ICAM-1- TARGET CELL BY TCRyS CTL 
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Ab ICAM-1- (IgR39) ICAM-I + (Licr-Lon) 
heteroconjugates’ Exp. I Exp. 2 Exp. 3 Exp. 4 Exp. 1 Exp. 2 Exp. 3 Exp. 4 
- - 15* 2 13 3 3 3 4 1 1  
- aCD18 X aDNP 40 6 37 9 7 3 5 13 
- aClassI X aDNP nt 2 16 3 nt 1 4 1 1  
aCD3 X aDNP - 24 11 44 29 49 37 59 74  
aCD3 X aDNP aCD18 X aDNP 42 31 70  56 49 46 69 76 
aCD3 X aDNP aClassI X aDNP nt 12 40 23 nt 33 63 68 
EffectorTCRys+/CD3+ clone: WIK. ‘Heteroconjugateconcentration aCD3 X aDNP = 0.1 &nl; aCD18 x aDNP = 0.1 pg/ml; aClassl x aDNP = 0.1 pg/ml.-*% 
specific lysis at an E/T ratio of 24. 
TCR-mediated lysis at a post-conjugate stage. LFA-1-specific 
MAbs reportedly block lysis by CTL and NK cells through 
inhibition of conjugate formation (Makgoba et al., 1988a; Leo 
et al., 1987). Here we show that, although anti-CD18 MAb 
inhibited CD-3 mediated cytolysis by CTL of ICAM-1- tumor 
cells, it did not affect their conjugate formation. These findings 
suggest that LFA- 1 can transduce down-regulatory signals after 
conjugate formation, although the possibility that the inhibitory 
effect of anti-CD18 MAb is solely due to decreased recycling 
of CTL is to be formally excluded. A further argument in favor 
of a signalling function for LFA-1 comes from our previously 
reported observation that ICAM- 1 - IgR39 tumor cells show a 
susceptibility to CD2-mediated lysis comparable to that of 
[CAM-1 + tumor cells (Goedegebuure et al., 1989). The rela- 
tive resistance of ICAM-1- target cells to CD3- but not CD2- 
mediated lysis demonstrates that it is not merely due to a de- 
creased conjugate-formating ability but suggests a signalling 
function for the LFA- l/ICAM- 1 interaction. Hetero-cross- 
linked anti-CD18 MAb enhanced MHC-unrestricted lysis of 
the ICAM-1- target cell by TCRy8’ CTL but not by 
TCRolP’ CTL in 2 out of 4 experiments. Still, LFA-1 cross- 
linking to the target cell per se is not sufficient to trigger the 
cytolytic machinery of TCRaP + and TCRyG + CTL because 
anti-LFA- 1 MAb-expressing hybridomas, cross-linking LFA- 
1, were not lysed by the CTL (Hoffman et al.,  1985; unpub- 
lished observation). Hence, LFA- 1 transduces a co-activation 
signal rather than a primary signal. Whether the functional 
interrelation between LFA-1 and the CD3/TCR complex de- 
pends on co-clustering of these molecules, as has been dem- 
onstrated for CD3/TCR and the accessory molecule CD4 
(Saizawa et al., 1987), remains to be established. 
In summary, our results demonstrate the central role of LFA- 
1 in T-cell activation. LFA-1 appears to be involved in CD3/ 
TCR-mediated lysis at 3 distinct stages of the lytic cycle. 
Firstly, as known, it promotes binding of CTL to target cells; 
secondly, it delivers co-stimulatory signals to CD3/TCR iin 
triggering cell-mediated lysis. Thirdly, it can transduce down- 
regulatory signals after conjugate formation, i . e .  antLCD1 8 
MAb inhibits CD3-mediated bispecific antibody-triggered ly- 
sis. Consequently, tumor cells lacking ICAM- 1 expression 
may escape lysis by CTL. The relative resistance of ICAM-l-- 
tumor cells to lysis might be overcome by the induction of 
ICAM-1 on the tumor-cell surface, e.g. with TNF or IFN-y 
(Dustin et al., 1986). Also, the use of antLCD2 x anti-target 
Abs which activate CTL independently of the additional LFA- 
l/ICAM-l interaction or the combined use of bispecific anti- 
CD3 X anti-target and anti-LFA-1 x anti-target Ab may in- 
duce efficient lysis of ICAM-1- target cells. 
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